FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:580-581 February 24, 2000 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Braun, S. PubMed Citation

Each year more than 180,000 women in the United States receive a diagnosis of breast cancer, and over 40,000 of them ultimately die of their disease. Larger primary tumors and tumor cells in axillary nodes are strong predictors of metastatic disease and death. In an effort to prevent these outcomes, women with tumor cells in axillary nodes routinely receive chemotherapy, hormonal therapy, or both, and radiation after surgery. Unfortunately, the predictive value of axillary-node status is limited. As many as 40 percent of women with positive axillary nodes survive 10 years, and metastatic disease develops within 10 years after diagnosis . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Diaz-Cano, S. J., Funke, I., Schraut, W., Pikarsky, E., Peretz, T., Braun, S., Schlimok, G., Pantel, K. (2000). Bone Marrow Metastases in Breast Cancer. NEJM 343: 577-578 [Full Text]  
• Hoey, J. (2000). Breast cancer and distant metastatic disease. CMAJ 163: 203-204 [Full Text]